BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

iCAD, Inc. (ICAD) Signs Development and Distribution Agreement with Agfa Corporation


6/12/2007 12:39:15 PM

NASHUA, N.H., June 12 /PRNewswire-FirstCall/ -- iCAD(R), Inc. , an industry-leading provider of Computer-Aided Detection (CAD) solutions, today announced signing of a development and distribution agreement with Agfa, a leading provider of IT enabled clinical workflow and diagnostic image solutions. With this agreement, iCAD's SecondLook Digital CAD solution is now available for Agfa's direct digital mammography systems. Agfa will market and sell this solution to customers globally, initially focusing on Europe and Asia. In the future, iCAD will develop a SecondLook Digital solution customized for Agfa's other market-leading mammography systems.

"We are encouraged by the broad scope of this agreement and look forward to working with Agfa to leverage our powerful systems together throughout the world," said Ken Ferry, President and CEO of iCAD. "We anticipate the collective iCAD and Agfa solution having an immediate impact in the market, particularly in Europe. Additionally, we believe iCAD and Agfa's collective future mammography solutions will significantly improve cancer detection and enhance digital workflow with CAD."

Using sophisticated algorithms, iCAD detection software enables earlier cancer detection which can allow less invasive and more effective treatment options, enhancing patient care. iCAD's algorithms have been shown to detect up to 72 percent of actionable missed cancers an average of 15 months earlier than mammography alone.

About Agfa Healthcare

Agfa offers a selection of proven solutions across the healthcare spectrum that includes conventional and digital imaging options as well as a complete range of information systems. Agfa customers around the world benefit from the combination of clinically specific features with hospital-wide connectivity, enabling a seamless flow of information and a 360-degree view of patients and healthcare facilities.

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of Computer- Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by almost one thousand women's healthcare centers worldwide. For more information, call +1 877 iCADnow or visit www.icadmed.com.

For iCAD investor relations, contact Kevin McGrath of Cameron Associates at 212-245-4577 or via email at kevin@cameronassoc.com For iCAD Public Relations, contact Wendy Ryan of Schwartz Communications at 781-684-0770 or via email at icad@schwartz-pr.com

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward- looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.

iCAD, Inc.

CONTACT: For iCAD investor relations, Kevin McGrath of Cameron Associates,+1-212-245-4577, kevin@cameronassoc.com; or for iCAD Public Relations,Wendy Ryan of Schwartz Communications, +1-781-684-0770,icad@schwartz-pr.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES